Fidelity Investments’s Impax Laboratories, Inc. IPXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
Sell
-4,802,713
Closed -$93.4M 2796
2018
Q1
$93.4M Buy
4,802,713
+4,577,913
+2,036% +$89.8M 0.01% 1013
2017
Q4
$3.74M Sell
224,800
-47,700
-18% -$874K ﹤0.01% 2230
2017
Q3
$5.53M Sell
272,500
-123,600
-31% -$2.36M ﹤0.01% 2130
2017
Q2
$6.38M Sell
396,100
-102,400
-21% -$1.51M ﹤0.01% 2100
2017
Q1
$6.31M Buy
498,500
+95,432
+24% +$1.15M ﹤0.01% 2119
2016
Q4
$5.34M Sell
403,068
-78,682
-16% -$1.35M ﹤0.01% 2164
2016
Q3
$11.4M Buy
481,750
+245,624
+104% +$6.6M ﹤0.01% 1932
2016
Q2
$6.8M Sell
236,126
-70,454
-23% -$2.3M ﹤0.01% 2107
2016
Q1
$9.82M Buy
306,580
+91,300
+42% +$3.21M ﹤0.01% 1974
2015
Q4
$9.21M Sell
215,280
-38,700
-15% -$1.55M ﹤0.01% 2021
2015
Q3
$8.94M Sell
253,980
-55,500
-18% -$2.5M ﹤0.01% 1992
2015
Q2
$14.2M Sell
309,480
-1,564,803
-83% -$74.3M ﹤0.01% 1879
2015
Q1
$87.8M Sell
1,874,283
-1,145,100
-38% -$45.6M 0.01% 1080
2014
Q4
$95.7M Buy
3,019,383
+722,200
+31% +$21.1M 0.01% 1028
2014
Q3
$54.5M Sell
2,297,183
-1,479,349
-39% -$37.9M 0.01% 1266
2014
Q2
$113M Sell
3,776,532
-447,955
-11% -$12.1M 0.02% 936
2014
Q1
$112M Sell
4,224,487
-315,934
-7% -$7.9M 0.02% 928
2013
Q4
$114M Buy
4,540,421
+182,845
+4% +$4.08M 0.02% 897
2013
Q3
$89.4M Sell
4,357,576
-572,098
-12% -$11.8M 0.01% 1008
2013
Q2
$98.3M Buy
+4,929,674
New +$87.5M 0.02% 924

Fidelity Investments's IPXL Position: Q2 2018 in Review

Fidelity Investments sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 4,802,713 shares — an estimated $93.4M sold.

Fidelity Investments first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $114M in Q4 2013. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

  • Fidelity Investments reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
  • Fidelity Investments sold 4,802,713 Impax Laboratories, Inc. shares in Q2 2018, an estimated $93.4M.
  • Fidelity Investments first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
  • Fidelity Investments's Impax Laboratories, Inc. position peaked at $114M in Q4 2013.
  • 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Fidelity Investments's 13F filing for Q2 2018, filed 10 Aug 2018.